
SXTC Valuation
China SXT Pharmaceuticals Inc
- Overview
- Forecast
- Valuation
- Earnings
SXTC Relative Valuation
SXTC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SXTC is overvalued; if below, it's undervalued.
Historical Valuation
China SXT Pharmaceuticals Inc (SXTC) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of China SXT Pharmaceuticals Inc (SXTC) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price:1.42
Fair
0.00
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
China SXT Pharmaceuticals Inc. (SXTC) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
0.00
EV/EBIT
China SXT Pharmaceuticals Inc. (SXTC) has a current EV/EBIT of 0.00. The 5-year average EV/EBIT is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBIT of 0.00 falls within the Strongly Undervalued range.
0.00
PS
China SXT Pharmaceuticals Inc. (SXTC) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.
0.00
P/OCF
China SXT Pharmaceuticals Inc. (SXTC) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/OCF of 0.00 falls within the Strongly Undervalued range.
0.00
P/FCF
China SXT Pharmaceuticals Inc. (SXTC) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.
China SXT Pharmaceuticals Inc (SXTC) has a current Price-to-Book (P/B) ratio of 1.27. Compared to its 3-year average P/B ratio of 0.29 , the current P/B ratio is approximately 332.25% higher. Relative to its 5-year average P/B ratio of 0.62, the current P/B ratio is about 104.70% higher. China SXT Pharmaceuticals Inc (SXTC) has a Forward Free Cash Flow (FCF) yield of approximately -1.39%. Compared to its 3-year average FCF yield of -66.05%, the current FCF yield is approximately -97.90% lower. Relative to its 5-year average FCF yield of -39.85% , the current FCF yield is about -96.52% lower.
1.27
P/B
Median3y
0.29
Median5y
0.62
-1.39
FCF Yield
Median3y
-66.05
Median5y
-39.85
Competitors Valuation Multiple
The average P/S ratio for SXTC's competitors is 1.78, providing a benchmark for relative valuation. China SXT Pharmaceuticals Inc Corp (SXTC) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of SXTC increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of SXTC in the past 1 year is driven by Unknown.
People Also Watch

TANH
Tantech Holdings Ltd
1.970
USD
-1.99%

GCTK
GlucoTrack Inc
5.040
USD
-5.26%

UPC
Universe Pharmaceuticals Inc
3.750
USD
+6.96%

SOBR
Sobr Safe Inc
3.430
USD
+3.00%

ADD
Zeta Network Group
1.487
USD
-20.69%

WNW
Meiwu Technology Co Ltd
1.780
USD
+1.77%

SGN
Signing Day Sports Inc
1.540
USD
-1.28%

SLXN
Silexion Therapeutics Corp
7.143
USD
-0.96%
FAQ

Is China SXT Pharmaceuticals Inc (SXTC) currently overvalued or undervalued?
China SXT Pharmaceuticals Inc (SXTC) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of China SXT Pharmaceuticals Inc (SXTC) is between to according to relative valuation methord.

What is China SXT Pharmaceuticals Inc (SXTC) fair value?

How does SXTC's valuation metrics compare to the industry average?

What is the current P/B ratio for China SXT Pharmaceuticals Inc (SXTC) as of Sep 03 2025?

What is the current FCF Yield for China SXT Pharmaceuticals Inc (SXTC) as of Sep 03 2025?

What is the current Forward P/E ratio for China SXT Pharmaceuticals Inc (SXTC) as of Sep 03 2025?
